Using integrated spatial transcriptome and multiomics analyses, we identified that differential expression characteristics of SOX17 and MCAM between UDB subtype (the highest) and other highly differentiated subtypes (relatively lower), and SOX17/MCAM expression was also significantly higher in metastatic BRCA patients than in nonmetastatic BRCA patients. This evidence concerns the gene SOX17 and invasive breast carcinoma.